Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

BACKGROUND: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribu...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Turiello, Roberta, Capone, Mariaelena, Giannarelli, Diana, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Mallardo, Domenico, Festino, Lucia, Azzaro, Rosa, Levesque, Mitchell P, Imhof, Laurence, Weide, Benjamin, Amaral, Teresa, Chevrier, Marc, Sucker, Antje, Rutkowski, Piotr, Schadendorf, Dirk, Lebbe, Celeste, Luke, Jason John, Wistuba-Hamprecht, Kilian, Dummer, Reinhard, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Immunotherapy Biomarkers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7759961/
https://ncbi.nlm.nih.gov/pubmed/33361405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001689
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items